Influence of COPD systemic environment on the myogenic function of muscle precursor cells in vitro

Casadevall Fusté, Carme; Sancho Muñoz, Antonio; Vicente, Ignacio; Pascual Guàrdia, Sergi, 1979-; Admetlló Papiol, Mireia; Gea Guiral, Joaquim

doi:http://dx.doi.org/10.1186/s12931-022-02203-6

Influence of COPD systemic environment on the myogenic function of muscle precursor cells in vitro

Llicència

Citació

Casadevall C, Sancho-Muñoz A, Vicente I, Pascual-Guardia S, Admetlló M, Gea J. Influence of COPD systemic environment on the myogenic function of muscle precursor cells in vitro. Respir Res. 2022 Oct 14;23(1):282. DOI: 10.1186/s12931-022-02203-6

Resum

Background: Loss of muscle mass and function are well-recognized systemic manifestations of chronic obstructive pulmonary disease (COPD). Acute exacerbations, in turn, significantly contribute to upgrade these systemic comorbidities. Involvement of myogenic precursors in muscle mass maintenance and recovery is poorly understood. The aim of the present study was to investigate the effects of the vascular systemic environment from stable and exacerbated COPD patients on the myogenic behavior of human muscle precursor cells (MPC) in vitro. Methods: Serum from healthy controls and from stable and exacerbated COPD patients (before and after Methylprednisolone treatment) was used to stimulate human MPC cultures. Proliferation analysis was assessed through BrdU incorporation assays. MPC differentiation was examined through real-time RT-PCR, western blot and immunofluorescence analysis. Results: Stimulation of MPCs with serum obtained from stable COPD patients did not affect myogenic precursor cell function. The vascular systemic environment during an acute exacerbation exerted a mitotic effect on MPCs without altering myogenic differentiation outcome. After Methylprednisolone treatment of acute exacerbated COPD patients, however, the mitotic effect was further amplified, but it was followed by a deficient differentiation capacity. Moreover, these effects were prevented when cells were co-treated with the glucocorticoid receptor antagonist Mifepristone. Conclusion: Our findings suggest that MPC capacity is inherently preserved in COPD patients, but is compromised after systemic administration of MP. This finding strengthens the concept that glucocorticoid treatment over the long term can negatively impact myogenic stem cell fate decisions and interfere with muscle mass recovery.